Interestingly, a study by Kamiya et al. showed that NKG2Anull NK cells, which were generated through transduction of anti-NKG2A protein expression blockers (PEBLs), exhibited relatively high cytotoxicity against HLA-E+ tumor cells; moreover, this method generated more potent cytotoxicity than blockade with an anti-NKG2A mAb (39), suggesting a new method for developing NKG2A-targeted cancer immunotherapy. Here, KLRC1 is linked to cancer.